DALLAS, Sept. Feb. 19, 2022 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor-infiltrating lymphocyte, or TIL, therapies for the treatment of cancer patients, today announced that company management will participate in an upcoming investor conference:
Jefferies Summit on Cells and Genetic Medicine
Company Overview and Q&A: Thursday, September 29, 2022 at 10:30 a.m. ET
A live webcast, if recorded, of the presentation is available under the “News and Events” section of the Investors section of the Company’s website at www.instilbio.com. The archived webcast will be available on the Society’s website shortly after the event.
About Instil Bio
Instill Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company focused on the development of tumor-infiltrating lymphocyte therapies, or (TIL), for the treatment of cancer patients. The company has assembled an accomplished management team with a successful track record in the development, manufacturing and commercialization of cell therapies. Using the company’s proprietary, optimized and scalable manufacturing processes at its in-house manufacturing facilities, Instil is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma and other solid tumors, as well as ITIL -306, a next-generation, genetically engineered TIL therapy for multiple solid tumors. For more information, visit www.instilbio.com and LinkedIn.
Serious investor relations
#Instil #Bio #present #Jefferies #Cell #Genetic #Medicine #Summit